Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
54% of the 922 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.02   Max: 44.56
Current: 0.03

0.02
44.56
Equity to Asset 0.22
MYL's Equity to Asset is ranked lower than
51% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MYL: 0.22 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.92
Current: 0.22

0.19
0.92
Interest Coverage 3.62
MYL's Interest Coverage is ranked higher than
51% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. MYL: 3.62 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 3.62

0.83
9.19
F-Score: 6
Z-Score: 2.27
M-Score: -2.65
WACC vs ROIC
7.52%
11.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.56
MYL's Operating margin (%) is ranked higher than
86% of the 872 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. MYL: 16.56 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 16.56

2.31
36
Net-margin (%) 12.36
MYL's Net-margin (%) is ranked higher than
85% of the 872 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.53 vs. MYL: 12.36 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 12.36

-3.53
30.52
ROE (%) 28.67
MYL's ROE (%) is ranked higher than
97% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.74 vs. MYL: 28.67 )
MYL' s 10-Year ROE (%) Range
Min: -8.33   Max: 21.55
Current: 28.67

-8.33
21.55
ROA (%) 6.20
MYL's ROA (%) is ranked higher than
82% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.79 vs. MYL: 6.20 )
MYL' s 10-Year ROA (%) Range
Min: -2.47   Max: 18.43
Current: 6.2

-2.47
18.43
ROC (Joel Greenblatt) (%) 31.96
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.01 vs. MYL: 31.96 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11   Max: 92.62
Current: 31.96

4.11
92.62
Revenue Growth (3Y)(%) 1.90
MYL's Revenue Growth (3Y)(%) is ranked higher than
66% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MYL: 1.90 )
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1   Max: 54.5
Current: 1.9

-6.1
54.5
EBITDA Growth (3Y)(%) 5.90
MYL's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 5.90 )
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20   Max: 107
Current: 5.9

-20
107
EPS Growth (3Y)(%) 32.40
MYL's EPS Growth (3Y)(%) is ranked higher than
91% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. MYL: 32.40 )
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8   Max: 110.4
Current: 32.4

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MYL Guru Trades in Q1 2014

Andreas Halvorsen 1,776,108 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Louis Moore Bacon 134,160 sh (New)
Jim Simons 1,401,474 sh (New)
Paul Tudor Jones 432,717 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Joel Greenblatt Sold Out
David Dreman Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75%)
» More
Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
Jean-Marie Eveillard 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
John Hussman 50,000 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
John Paulson 12,130,700 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3%)
John Hussman 50,000 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Pioneer Investments 282,805 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
Jean-Marie Eveillard 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
Jean-Marie Eveillard 841,779 sh (+3.97%)
Louis Moore Bacon 200,000 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.7%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-12-31 Add 19.64%0.72%$46.5 - $58.62 $ 57.336%14948400
Joel Greenblatt 2014-12-31 New Buy0.31%$46.5 - $58.62 $ 57.336%673287
Scott Black 2014-12-31 Reduce -8.83%0.11%$46.5 - $58.62 $ 57.337%181796
Vanguard Health Care Fund 2014-09-30 Add 223.41%1.24%$44.97 - $52.34 $ 57.3318%15444880
Jean-Marie Eveillard 2014-09-30 Reduce -34.81%0.06%$44.97 - $52.34 $ 57.3318%809603
Ray Dalio 2014-09-30 New Buy0.02%$44.97 - $52.34 $ 57.3318%57106
Mario Gabelli 2014-09-30 Reduce -27.54%$44.97 - $52.34 $ 57.3318%10000
Scott Black 2014-06-30 Reduce -26.46%0.4%$45.72 - $52.1 $ 57.3317%201925
Andreas Halvorsen 2014-06-30 Sold Out 0.36%$45.72 - $52.1 $ 57.3317%0
Jean-Marie Eveillard 2014-06-30 Add 83.88%0.07%$45.72 - $52.1 $ 57.3317%1241991
John Hussman 2014-03-31 Reduce -75%0.47%$42.26 - $57.2 $ 57.3319%50000
Andreas Halvorsen 2014-03-31 New Buy0.36%$42.26 - $57.2 $ 57.3318%1776108
Scott Black 2014-03-31 Reduce -10.63%0.16%$42.26 - $57.2 $ 57.3319%274571
Jean-Marie Eveillard 2014-03-31 New Buy0.09%$42.26 - $57.2 $ 57.3318%675428
Joel Greenblatt 2014-03-31 Sold Out 0.01%$42.26 - $57.2 $ 57.3318%0
David Dreman 2014-03-31 Sold Out $42.26 - $57.2 $ 57.3318%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Mylan Inc

Scott Black’s Top First Quarter Holdings
Scott Black is the chairman, president, chief investment officer and founder of Boston-based Delphi Management, and is often featured in Barron’s. Delphi Management’s investment philosophy states that they “only invest in companies that meet our internally developed set of rigorous quantitative criteria.” The fund also only invests in equity securities of US-listed companies, and takes only long positions. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.70
MYL's P/E(ttm) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.00 vs. MYL: 24.70 )
MYL' s 10-Year P/E(ttm) Range
Min: 7.05   Max: 112.56
Current: 24.7

7.05
112.56
Forward P/E 12.42
MYL's Forward P/E is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.61 vs. MYL: 12.42 )
N/A
PE(NRI) 24.70
MYL's PE(NRI) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.80 vs. MYL: 24.70 )
MYL' s 10-Year PE(NRI) Range
Min: 7.05   Max: 200.11
Current: 24.7

7.05
200.11
P/B 6.33
MYL's P/B is ranked higher than
59% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MYL: 6.33 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 7.02
Current: 6.33

0.64
7.02
P/S 3.06
MYL's P/S is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. MYL: 3.06 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 4.89
Current: 3.06

0.41
4.89
PFCF 36.06
MYL's PFCF is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 36.06 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 82
Current: 36.06

8.81
82
POCF 17.43
MYL's POCF is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.08 vs. MYL: 17.43 )
MYL' s 10-Year POCF Range
Min: 6.09   Max: 40.56
Current: 17.43

6.09
40.56
EV-to-EBIT 22.56
MYL's EV-to-EBIT is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.12 vs. MYL: 22.56 )
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7   Max: 28.8
Current: 22.56

-10.7
28.8
PEG 2.49
MYL's PEG is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 2.49 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 2.49

0.37
11.64
Shiller P/E 46.94
MYL's Shiller P/E is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.35 vs. MYL: 46.94 )
MYL' s 10-Year Shiller P/E Range
Min: 10.98   Max: 701
Current: 46.94

10.98
701
Current Ratio 1.30
MYL's Current Ratio is ranked higher than
55% of the 896 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.45 vs. MYL: 1.30 )
MYL' s 10-Year Current Ratio Range
Min: 1.3   Max: 8.52
Current: 1.3

1.3
8.52
Quick Ratio 0.92
MYL's Quick Ratio is ranked higher than
55% of the 896 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. MYL: 0.92 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.76
Current: 0.92

0.85
6.76
Days Inventory 152.53
MYL's Days Inventory is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. MYL: 152.53 )
MYL' s 10-Year Days Inventory Range
Min: 88.95   Max: 177.15
Current: 152.53

88.95
177.15
Days Sales Outstanding 84.97
MYL's Days Sales Outstanding is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.09 vs. MYL: 84.97 )
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61   Max: 101.71
Current: 84.97

49.61
101.71

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.44
MYL's Price/DCF (Projected) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.51 vs. MYL: 2.44 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.51
Current: 2.44

0.62
2.51
Price/Median PS Value 1.68
MYL's Price/Median PS Value is ranked higher than
66% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. MYL: 1.68 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.73
Current: 1.68

0.36
3.73
Price/Peter Lynch Fair Value 2.56
MYL's Price/Peter Lynch Fair Value is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 2.56 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 10.2
Current: 2.56

0.67
10.2
Earnings Yield (Greenblatt) 4.40
MYL's Earnings Yield (Greenblatt) is ranked higher than
83% of the 923 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 4.40 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15.1
Current: 4.4

3.5
15.1
Forward Rate of Return (Yacktman) 12.18
MYL's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. MYL: 12.18 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.6   Max: 39.2
Current: 12.18

3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MYL.Germany, MYL.Switzerland,
Mylan Inc was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted primarily in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
John Paulson's Top Buys Feb 21 2015 
Weekly CFO Sells Highlight: Sherwin-Williams Co, Facebook Inc, Mylan Inc. Feb 08 2015 
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Weekly Insider Sells Highlight: MYL, QRVO, HON, JBHT Feb 08 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Scott Black’s Top First Quarter Holdings Apr 23 2014 
Should You Buy Actavis? Mar 18 2014 


More From Other Websites
Intercept Pharmaceuticals (ICPT): Will It Miss Q4 Earnings? - Analyst Blog Feb 28 2015
Next Week Feb 28 2015
Mylan inversion deal completed Feb 27 2015
Will Endo Internationa's (ENDP) Beat on Earnings in Q4? - Analyst Blog Feb 27 2015
MYLAN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition... Feb 27 2015
Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog Feb 27 2015
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India Feb 27 2015
Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics... Feb 27 2015
12:30 pm Mylan Labs announces the successful completion of the acquisition of Abbott Laboratories'... Feb 27 2015
Is a Surprise Coming for Mylan (MYL) This Earnings Season? - Tale of the Tape Feb 27 2015
What Awaits Keryx Biopharmaceuticals (KERX) this Earnings? - Analyst Blog Feb 26 2015
Lannett Joins Big-Game Hunt For Drugmaker Acquisitions Feb 24 2015
Watchdog group seeks FDA ban of antifungal tablets Feb 24 2015
Watchdog group seeks FDA ban of antifungal tablets Feb 24 2015
Five Top-Rated Medical Stocks To Keep Monitoring Feb 23 2015
Drugmaker Mylan Takes Part In Pharma Feeding Frenzy Feb 23 2015
Pharma M&A: Bristol-Myers, Valeant Make Deals Feb 23 2015
Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey Feb 23 2015
Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey Feb 23 2015
Mylan to Distribute Gilead's Hepatitis C Drugs in India Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK